Immunitybio is trading at $9.89, up 6.63%, amid broader market strength.
- No clear company-specific announcement explaining the rise surfaced in the search.
- ImmunityBio is scheduled to present at the Thoracic Rare Cancer Symposium on October 2, but the event listing alone does not establish it as the catalyst.
- Major indexes are up more than 0.5% per the supplied market context; Reuters reports U.S. indexes rose after the weak September jobs report.